Search

Your search keyword '"Brandes A.A."' showing total 195 results
Start Over Author "Brandes A.A."
195 results on '"Brandes A.A."'

1. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Author

Pellegrino, B., Cavanna, L., Boggiani, D., Zamagni, C., Frassoldati, A., Schirone, A., Caldara, A., Rocca, A., Gori, S., Piacentini, F., Berardi, R., Brandes, A.A., Foglietta, J., Villa, F., Todeschini, R., Tognetto, M., Naldi, N., Bortesi, B., Montemurro, F., Ardizzoni, A., Boni, L., and Musolino, A.

Published
2021
Full Text
View/download PDF

2. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

Author

Dieci, M.V., Conte, P., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Piacentini, F., Maiorana, A., Orvieto, E., Sanders, M., Miglietta, F., Balduzzi, S., D’Amico, R., and Guarneri, V.

Published
2019
Full Text
View/download PDF

3. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Author

Conte, P., Frassoldati, A., Bisagni, G., Brandes, A.A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E.A., Vicini, R., Balduzzi, S., D’Amico, R., and Guarneri, V.

Published
2018
Full Text
View/download PDF

4. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Author

Gao, Y., Weenink, B., van den Bent, M.J., Erdem-Eraslan, L., Kros, J.M., Sillevis Smitt, PAE, Hoang-Xuan, K., Brandes, A.A., Vos, M., Dhermain, F., Enting, R., Ryan, G.F., Chinot, O., Ben Hassel, M., van Linde, M.E., Mason, W.P., Gijtenbeek, J.M.M., Balana, C., von Deimling, A., Gorlia, Th, Stupp, R., Hegi, M.E., Baumert, B.G., and French, P.J.

Published
2018
Full Text
View/download PDF

5. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

Author

Coomans, M., Dirven, L., Aaronson, N., Baumert, B.G., Bent, M. van den, Bottomley, A., Brandes, A.A., Chinot, O., Coens, C., Gorlia, T., Herrlinger, U., Keime-Guibert, F., Malmstrom, A., Martinelli, F., Stupp, R., Talacchi, A., Weller, M., Wick, W., Reijneveld, J.C., Taphoorn, M.J.B., EORTC Quality Life Grp, EORTC Brain Tumor Grp, Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Neuro-Oncologie [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), University of Zurich, Neurology, CCA - Cancer Treatment and quality of life, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
REHABILITATION, Cancer Research, [SDV]Life Sciences [q-bio], BEVACIZUMAB, EUROPEAN-ORGANIZATION, 610 Medicine & health, LOMUSTINE, time-to-deterioration, SDG 3 - Good Health and Well-being, CRITERIA, Humans, brain tumor, deterioration-free-survival, progressive disease, Cancer och onkologi, Brain Neoplasms, TEMOZOLOMIDE, Glioma, Progression-Free Survival, humanities, 10040 Clinic for Neurology, ANAPLASTIC OLIGODENDROGLIOMA, Oncology, Cancer and Oncology, PHASE-II, Quality of Life, TRIAL, Neurology (clinical), RESPONSE ASSESSMENT
Abstract

Background Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period. Methods We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period. Results Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9–29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8–5.4 months, and median time-to-deterioration between 8.2–11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period. Conclusions HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients’ functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled.

Published
2022

6. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Mangano, S., Tonato, M., Zucca, E., Valsecchi, M.G., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., Dell'Oro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

9. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Author

Bent, M.J. van den, Tesileanu, C.M.S., Wick, W., Sanson, M., Brandes, A.A., Clement, P.M., Erridge, S., Vogelbaum, M.A., Nowak, A.K., Baurain, J.F., Mason, W.P., Wheeler, H., Chinot, O.L., Gill, S., Griffin, M., Rogers, L., Taal, W., Rudà, R., Weller, M., McBain, C., Reijneveld, J., Enting, R.H., Caparrotti, F., Lesimple, T., Clenton, S., Gijtenbeek, A., Lim, E., Herrlinger, U., Hau, P., Dhermain, F., Heer, I. de, Aldape, K., Jenkins, R.B., Dubbink, H.J., Kros, J.M., Wesseling, P., Nuyens, S., Golfinopoulos, V., Gorlia, T., French, P., Baumert, B.G., Bent, M.J. van den, Tesileanu, C.M.S., Wick, W., Sanson, M., Brandes, A.A., Clement, P.M., Erridge, S., Vogelbaum, M.A., Nowak, A.K., Baurain, J.F., Mason, W.P., Wheeler, H., Chinot, O.L., Gill, S., Griffin, M., Rogers, L., Taal, W., Rudà, R., Weller, M., McBain, C., Reijneveld, J., Enting, R.H., Caparrotti, F., Lesimple, T., Clenton, S., Gijtenbeek, A., Lim, E., Herrlinger, U., Hau, P., Dhermain, F., Heer, I. de, Aldape, K., Jenkins, R.B., Dubbink, H.J., Kros, J.M., Wesseling, P., Nuyens, S., Golfinopoulos, V., Gorlia, T., French, P., and Baumert, B.G.

Abstract

Item does not contain fulltext, BACKGROUND: The CATNON trial investigated the addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas. The benefit of concurrent temozolomide chemotherapy and relevance of mutations in the IDH1 and IDH2 genes remain unclear. METHODS: This randomised, open-label, phase 3 study done in 137 institutions across Australia, Europe, and North America included patients aged 18 years or older with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas and a WHO performance status of 0-2. Patients were randomly assigned (1:1:1:1) centrally using a minimisation technique to radiotherapy alone (59·4 Gy in 33 fractions; three-dimensional conformal radiotherapy or intensity-modulated radiotherapy), radiotherapy with concurrent oral temozolomide (75 mg/m(2) per day), radiotherapy with adjuvant oral temozolomide (12 4-week cycles of 150-200 mg/m(2) temozolomide given on days 1-5), or radiotherapy with both concurrent and adjuvant temozolomide. Patients were stratified by institution, WHO performance status score, age, 1p loss of heterozygosity, the presence of oligodendroglial elements on microscopy, and MGMT promoter methylation status. The primary endpoint was overall survival adjusted by stratification factors at randomisation in the intention-to-treat population. A second interim analysis requested by the independent data monitoring committee was planned when two-thirds of total required events were observed to test superiority or futility of concurrent temozolomide. This study is registered with ClinicalTrials.gov, NCT00626990. FINDINGS: Between Dec 4, 2007, and Sept 11, 2015, 751 patients were randomly assigned (189 to radiotherapy alone, 188 to radiotherapy with concurrent temozolomide, 186 to radiotherapy and adjuvant temozolomide, and 188 to radiotherapy with concurrent and adjuvant temozolomide). Median follow-up was 55·7 months (IQR 41·0-77·3). The second interi

Published
2021

10. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

Author

Tesileanu, C.M.S., Vallentgoed, W.R., Sanson, M., Taal, W., Clement, P.M., Wick, W., Brandes, A.A., Baurain, J.F., Chinot, O.L., Wheeler, H., Gill, S., Griffin, M., Rogers, L., Rudà, R., Weller, M., McBain, C., Reijneveld, J., Enting, R.H., Caparrotti, F., Lesimple, T., Clenton, S., Gijtenbeek, A., Lim, E., Vos, F., Mulholland, P.J., Taphoorn, M.J., Heer, I. de, Hoogstrate, Y., Wit, M. de, Boggiani, L., Venneker, S., Oosting, J., Bovée, J., Erridge, S., Vogelbaum, M.A., Nowak, A.K., Mason, W.P., Kros, J.M., Wesseling, P., Aldape, K., Jenkins, R.B., Dubbink, H.J., Baumert, B., Golfinopoulos, V., Gorlia, T., Bent, M. van den, French, P.J., Tesileanu, C.M.S., Vallentgoed, W.R., Sanson, M., Taal, W., Clement, P.M., Wick, W., Brandes, A.A., Baurain, J.F., Chinot, O.L., Wheeler, H., Gill, S., Griffin, M., Rogers, L., Rudà, R., Weller, M., McBain, C., Reijneveld, J., Enting, R.H., Caparrotti, F., Lesimple, T., Clenton, S., Gijtenbeek, A., Lim, E., Vos, F., Mulholland, P.J., Taphoorn, M.J., Heer, I. de, Hoogstrate, Y., Wit, M. de, Boggiani, L., Venneker, S., Oosting, J., Bovée, J., Erridge, S., Vogelbaum, M.A., Nowak, A.K., Mason, W.P., Kros, J.M., Wesseling, P., Aldape, K., Jenkins, R.B., Dubbink, H.J., Baumert, B., Golfinopoulos, V., Gorlia, T., Bent, M. van den, and French, P.J.

Abstract

Contains fulltext : 235663.pdf (Publisher’s version ) (Open Access), Somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that gliomas are the only tumour type with an exceptionally high percentage of IDH1(R132H) mutations. Patients harbouring IDH1(R132H) mutated tumours have lower levels of genome-wide DNA-methylation, and an associated increased gene expression, compared to tumours with other IDH1/2 mutations ("non-R132H IDH1/2 mutations"). This reduced methylation is seen in multiple tumour types and thus appears independent of the site of origin. For 1p/19q non-codeleted glioma (astrocytoma) patients, we show that this difference is clinically relevant: in samples of the randomised phase III CATNON trial, patients harbouring tumours with IDH mutations other than IDH1(R132H) have a better outcome (hazard ratio 0.41, 95% CI [0.24, 0.71], p = 0.0013). Such non-R132H IDH1/2-mutated tumours also had a significantly lower proportion of tumours assigned to prognostically poor DNA-methylation classes (p < 0.001). IDH mutation-type was independent in a multivariable model containing known clinical and molecular prognostic factors. To confirm these observations, we validated the prognostic effect of IDH mutation type on a large independent dataset. The observation that non-R132H IDH1/2-mutated astrocytomas have a more favourable prognosis than their IDH1(R132H) mutated counterpart indicates that not all IDH-mutations are identical. This difference is clinically relevant and should be taken into account for patient prognostication.

Published
2021

11. Measuring change in health-related quality of life

Author

Coomans, M.B., Taphoorn, M.J.B., Aaronson, N.K., Baumert, B.G., Bent, M. van den, Bottomley, A., Brandes, A.A., Chinot, O., Coens, C., Gorlia, T., Herrlinger, U., Keime-Guibert, F., Malmstrom, A., Martinelli, F., Stupp, R., Talacchi, A., Weller, M., Wick, W., Reijneveld, J.C., Dirven, L., EORTC Quality Life Grp, EORTC Brain Tumor Grp, Neurology, CCA - Cancer Treatment and quality of life, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
0301 basic medicine, medicine.medical_specialty, BEVACIZUMAB, Medicine (miscellaneous), patient-reported outcome, VALIDATION, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, Clinical decision making, law, medicine, AcademicSubjects/MED00300, Sjukgymnastik, Group level, Physiotherapy, Change score, Health related quality of life, business.industry, brain tumor, quality of life, questionnaire, Original Articles, Editor's Choice, 030104 developmental biology, 030220 oncology & carcinogenesis, Scale (social sciences), Physical therapy, Patient-reported outcome, AcademicSubjects/MED00310, business
Abstract

Background Different analytical methods may lead to different conclusions about the impact of treatment on health-related quality of life (HRQoL). This study aimed to examine 3 different methods to evaluate change in HRQoL and to study whether these methods result in different conclusions. Methods HRQoL data from 15 randomized clinical trials were combined (CODAGLIO project). Change in HRQoL scores, measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and BN20 questionnaires, was analyzed in 3 ways: (1) at the group level, comparing mean changes in scale/item scores between treatment arms, (2) at the patient level per scale/item, calculating the percentage of patients that deteriorated, improved, or remained stable per scale/item, and (3) at the individual patient level, combining all scales/items. Results Baseline and first follow-up HRQoL data were available for 3727 patients. At the group scale/item level, only the item “hair loss” showed a significant and clinically relevant change (ie, ≥10 points) over time, whereas change scores on the other scales/items were statistically significant only (all P Conclusions Different analytical methods of changes in HRQoL result in distinct conclusions of treatment effects, all of which may be relevant for informing clinical decision making.

Published
2020

12. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Bajetta, E., Floriani, I., Di Bartolomeo, M., Labianca, R., Falcone, A., Di Costanzo, F., Comella, G., Amadori, D., Pinto, C., Carlomagno, C., Nitti, D., Daniele, B., Mini, E., Poli, D., Santoro, A., Mosconi, S., Casaretti, R., Boni, C., Pinotti, G., Bidoli, P., Landi, L., Rosati, G., Ravaioli, A., Cantore, M., Di Fabio, F., Aitini, E., Marchet, A., Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Poli, D., Mangano, S., Tonato, M., Zucca, E., Valsecchi, MG., Floriani, I., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Bajetta, E., Di Bartolomeo, M., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., DellʼOro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Labianca, R., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Amadori, D., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Falcone, A., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Di Costanzo, F., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Pinto, C., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Daniele, B., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Nitti, D., Marchet, A., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

13. 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

Author

Conte, P.F., primary, Frassoldati, A., additional, Bisagni, G., additional, Brandes, A.A., additional, Donadio, M., additional, Garrone, O., additional, Piacentini, F., additional, Cavanna, L., additional, Giotta, F., additional, Aieta, M., additional, Gebbia, V., additional, Musolino, A., additional, Ferro, A., additional, Danese, S., additional, Zamagni, C., additional, Nanni, O., additional, Dieci, M.V., additional, Vicini, R., additional, Balduzzi, S., additional, and Guarneri, V., additional

Published
2021
Full Text
View/download PDF

14. Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Trial

Author

Song, A.J., primary, Ding, K., additional, Laperriere, N.J., additional, Perry, J., additional, Mason, W.P., additional, Winch, C., additional, O'Callaghan, C.J., additional, Menten, J., additional, Brandes, A.A., additional, Phillips, C., additional, Fay, M.F., additional, Nishikawa, R., additional, Osoba, D., additional, Cairncross, G., additional, Roa, W., additional, Wick, W., additional, and Shi, W., additional

Published
2020
Full Text
View/download PDF

15. 367MO Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective, observational study

Author

Gatto, L., primary, Tosoni, A., additional, Franceschi, E., additional, Di Nunno, V., additional, Minichillo, S., additional, Mura, A., additional, Di Battista, M., additional, Lamperini, C., additional, Mosca, M., additional, Nuvola, G., additional, Sisi, M., additional, Bartolini, S., additional, and Brandes, A.A., additional

Published
2020
Full Text
View/download PDF

17. 19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study

Author

Guarneri, V., primary, Dieci, M.V., additional, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Cavanna, L., additional, Musolino, A., additional, Giotta, F., additional, Rimanti, A., additional, Garrone, O., additional, Bertone, E., additional, Cagossi, K., additional, Nanni, O., additional, Piacentini, F., additional, Orvieto, E., additional, Curtarello, M., additional, Chic, N., additional, D'Amico, R., additional, Prat, A., additional, and Conte, P.F., additional

Published
2020
Full Text
View/download PDF

20. Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

Author

Lombardi, G., primary, Del Bianco, P., additional, Brandes, A.A., additional, Eoli, M., additional, Rudà, R., additional, Ibrahim, T., additional, Lolli, I.R., additional, Pace, A., additional, Daniele, B., additional, Pasqualetti, F., additional, Rizzato, S., additional, Bergo, E., additional, Caccese, M., additional, Padovan, M., additional, Soffietti, R., additional, De Salvo, G.L., additional, and Zagonel, V., additional

Published
2019
Full Text
View/download PDF

21. Dosimetric Analysis, Acute Toxicity and Long-Term Outcome of Craniospinal Irradiation Using Helical Tomotherapy in Children and Adults

Author

Coassin, E., primary, Drigo, A., additional, Chiovati, P., additional, Polesel, J., additional, Gigante, M., additional, Cinalli, G., additional, Masotto, B., additional, Passone, E., additional, Kiren, V., additional, Sartor, G., additional, Franchin, G., additional, Brandes, A.A., additional, and Mascarin, M., additional

Published
2019
Full Text
View/download PDF

22. Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial

Author

Dieci, M.V., primary, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Donadio, M., additional, Garrone, O., additional, Piacentini, F., additional, Balduzzi, S., additional, Guarneri, V., additional, and Conte, P.F., additional

Published
2019
Full Text
View/download PDF

28. Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Author

Dieci, M.V., primary, Conte, P.F., additional, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Cavanna, L., additional, Musolino, A., additional, Giotta, F., additional, Rimanti, A., additional, Garrone, O., additional, Bertone, E., additional, Cagossi, K., additional, Sarti, S., additional, Ferro, A., additional, Omarini, C., additional, Maiorana, A., additional, Orvieto, E., additional, Sanders, M., additional, D'Amico, R., additional, and Guarneri, V., additional

Published
2018
Full Text
View/download PDF

29. 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Author

Conte, P.F., primary, Guarneri, V., additional, Bisagni, G., additional, Piacentini, F., additional, Brandes, A.A., additional, Cavanna, L., additional, Giotta, F., additional, Aieta, M., additional, Gebbia, V., additional, Frassoldati, A., additional, Musolino, A., additional, Garrone, O., additional, Taverniti, C., additional, Rimanti, A., additional, Sarti, S., additional, Rubino, D., additional, Bologna, A., additional, Vicini, R., additional, Balduzzi, S., additional, and D'Amico, R., additional

Published
2018
Full Text
View/download PDF

30. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Author

Bent, M.J. van den, Baumert, B., Erridge, S.C., Vogelbaum, M.A., Nowak, A.K., Sanson, M., Brandes, A.A., Clement, P.M., Baurain, J.F., Mason, W.P., Wheeler, H., Chinot, O.L., Gill, S., Griffin, M., Brachman, D.G., Taal, W., Ruda, R., Weller, M., McBain, C., Reijneveld, J., Enting, R.H., Weber, D.C., Lesimple, T., Clenton, S., Gijtenbeek, A., Pascoe, S., Herrlinger, U., Hau, P., Dhermain, F., Heuvel, I. van, Stupp, R., Aldape, K., Jenkins, R.B., Dubbink, H.J., Dinjens, W.N., Wesseling, P., Nuyens, S., Golfinopoulos, V., Gorlia, T., Wick, W., Kros, J.M., Bent, M.J. van den, Baumert, B., Erridge, S.C., Vogelbaum, M.A., Nowak, A.K., Sanson, M., Brandes, A.A., Clement, P.M., Baurain, J.F., Mason, W.P., Wheeler, H., Chinot, O.L., Gill, S., Griffin, M., Brachman, D.G., Taal, W., Ruda, R., Weller, M., McBain, C., Reijneveld, J., Enting, R.H., Weber, D.C., Lesimple, T., Clenton, S., Gijtenbeek, A., Pascoe, S., Herrlinger, U., Hau, P., Dhermain, F., Heuvel, I. van, Stupp, R., Aldape, K., Jenkins, R.B., Dubbink, H.J., Dinjens, W.N., Wesseling, P., Nuyens, S., Golfinopoulos, V., Gorlia, T., Wick, W., and Kros, J.M.

Abstract

Item does not contain fulltext, BACKGROUND: The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas. METHODS: This was a phase 3, randomised, open-label study with a 2 x 2 factorial design. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with WHO performance status scores of 0-2. The randomisation schedule was generated with the electronic EORTC web-based ORTA system. Patients were assigned in equal numbers (1:1:1:1), using the minimisation technique, to receive radiotherapy (59.4 Gy in 33 fractions of 1.8 Gy) alone or with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m(2) temozolomide given on days 1-5); or to receive radiotherapy with concurrent temozolomide 75 mg/m(2) per day, with or without adjuvant temozolomide. The primary endpoint was overall survival adjusted for performance status score, age, 1p loss of heterozygosity, presence of oligodendroglial elements, and MGMT promoter methylation status, analysed by intention to treat. We did a planned interim analysis after 219 (41%) deaths had occurred to test the null hypothesis of no efficacy (threshold for rejection p<0.0084). This trial is registered with ClinicalTrials.gov, number NCT00626990. FINDINGS: At the time of the interim analysis, 745 (99%) of the planned 748 patients had been enrolled. The hazard ratio for overall survival with use of adjuvant temozolomide was 0.65 (99.145% CI 0.45-0.93). Overall survival at 5 years was 55.9% (95% CI 47.2-63.8) with and 44.1% (36.3-51.6) without adjuvant temozolomide. Grade 3-4 adverse events were seen in 8-12% of 549 patients assigned temozolomide, and were mainly haematological and reversible. INTERPRETATION: Adjuvant temozolomide chemotherapy

Published
2017

31. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Author

Reijneveld, J.C., Taphoorn, M.J.B., Coens, C., Bromberg, J.E.C., Mason, W.P., Hoang-Xuan, K., Ryan, G., Hassel, M. ben, Enting, R.H., Brandes, A.A., Wick, A., Chinot, O., Reni, M., Kantor, G., Thiessen, B., Klein, M., Verger, E., Borchers, C., Hau, P., Back, M., Smits, A., Golfinopoulos, V., Gorlia, T., Bottomley, A., Stupp, R., and Baumert, B.G.

Published
2016

32. The role of clinical and molecular characteristics in low grade gliomas

Author

Mura, A., primary, Franceschi, E., additional, Minichillo, S., additional, Tosoni, A., additional, Fioravanti, A., additional, Talacchi, A., additional, Volpin, L., additional, Tallini, G., additional, De Biase, D., additional, Visani, M., additional, Degli Esposti, R., additional, Genestreti, G., additional, Pizzolitto, S., additional, Agati, R., additional, Bortolotti, C., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

33. IDH mutant and 1p19q codeleted low grade gliomas: to treat or not to treat?

Author

Tosoni, A., primary, Franceschi, E., additional, Mura, A., additional, Minichillo, S., additional, Pession, A., additional, De Biase, D., additional, Danieli, D., additional, Pizzolitto, S., additional, Fioravanti, A., additional, Volpin, L., additional, Agati, R., additional, Genestreti, G., additional, Degli Esposti, R., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

34. The role of treatments in IDH mutant molecular astrocytomas

Author

Minichillo, S., primary, Franceschi, E., additional, Mura, A., additional, Tosoni, A., additional, Tallini, G., additional, Pession, A., additional, Foschini, M., additional, Bortolotti, C., additional, Danieli, D., additional, Talacchi, A., additional, Cirillo, L., additional, Di Battista, M., additional, Genestreti, G., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

35. Gender and MGMT methylation in glioblastoma patients: interactions in the PERNO prospective study

Author

Franceschi, E., primary, Tosoni, A., additional, Depenni, R., additional, Urbini, B., additional, Faedi, M., additional, Michiara, M., additional, Biasini, C., additional, Giombelli, E., additional, Pavesi, G., additional, Zanelli, F., additional, Cavallo, M.A., additional, Tosatto, L., additional, Fioravanti, A., additional, Zunarelli, E., additional, Lanza, G., additional, Bartolini, D., additional, Silini, E.M., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

36. REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients

Author

Lombardi, G., primary, De Salvo, G.L., additional, Brandes, A.A., additional, Eoli, M., additional, Rudà, R., additional, Faedi, M., additional, Lolli, I., additional, Pace, A., additional, Rizzato, S., additional, Germano, D., additional, Pasqualetti, F., additional, Farina, M., additional, Magni, G., additional, Pambuku, A., additional, Bergo, E., additional, Cabrini, G., additional, Indraccolo, S., additional, Gardiman, M.P., additional, and Zagonel, V., additional

Published
2017
Full Text
View/download PDF

37. The prognostic role of gender and MGMT methylation status in glioblastoma patients: The female power

Author

Tosoni, A., primary, Franceschi, E., additional, Depenni, R., additional, Urbini, B., additional, Faedi, M., additional, Michiara, M., additional, Biasini, C., additional, Giombelli, E., additional, Pavesi, G., additional, Zanelli, F., additional, Cavallo, M.A., additional, Tosatto, L., additional, Fioravanti, A., additional, Zunarelli, E., additional, Lanza, G., additional, Bartolini, D., additional, Silini, E.M., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

38. IDH wild type low grade gliomas: Who seeks shall find

Author

Mandrioli, A., primary, Franceschi, E., additional, Minichillo, S., additional, Mura, A., additional, Tosoni, A., additional, De Biase, D., additional, Zunarelli, E., additional, Lanza, G., additional, Bartolini, D., additional, Silini, E.M., additional, Tallini, G., additional, Cirillo, L., additional, Bortolotti, C., additional, Danieli, D., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

39. The role of clinical characteristics in low grade gliomas in molecular era

Author

Mura, A., primary, Franceschi, E., additional, Minichillo, S., additional, Mandrioli, A., additional, Tosoni, A., additional, Fioravanti, A., additional, Talacchi, A., additional, Volpin, L., additional, Tallini, G., additional, De Biase, D., additional, Agati, R., additional, Pizzolitto, S., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

40. Prognostic factors for IDH mutant molecular astrocytomas

Author

Minichillo, S., primary, Franceschi, E., additional, Mura, A., additional, Mandrioli, A., additional, Tosoni, A., additional, Tallini, G., additional, Pession, A., additional, Foschini, M.P., additional, Bortolotti, C., additional, Danieli, D., additional, Talacchi, A., additional, Cirillo, L., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

41. Low grade glioma patients with IDH mutation and 1p19q codeletion: What to do after surgery?

Author

Franceschi, E., primary, Mura, A., additional, Mandrioli, A., additional, Minichillo, S., additional, Tosoni, A., additional, Pession, A., additional, De Biase, D., additional, Danieli, D., additional, Pizzolitto, S., additional, Fioravanti, A., additional, Volpin, L., additional, Agati, R., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

42. Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Author

Lim, M., primary, Omuro, A., additional, Vlahovic, G., additional, Reardon, D.A., additional, Sahebjam, S., additional, Cloughesy, T., additional, Baehring, J., additional, Butowski, N., additional, Potter, V., additional, Zwirtes, R., additional, Paliwal, P., additional, Carleton, M., additional, Sampson, J., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

43. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Author

Baumert, B.G., Hegi, M.E., Bent, M.J. van den, Deimling, A. von, Gorlia, T., Hoang-Xuan, K., Brandes, A.A., Kantor, G., Taphoorn, M.J., Hassel, M.B., Hartmann, C., Ryan, G., Capper, D., Kros, J.M., Kurscheid, S., Wick, W., Enting, R., Reni, M., Thiessen, B., Dhermain, F., Bromberg, J.E., Feuvret, L., Reijneveld, J.C., Chinot, O., Gijtenbeek, J.M.M., Rossiter, J.P., Dif, N., Balana, C., Bravo-Marques, J., Clement, P.M., Marosi, C., Tzuk-Shina, T., Nordal, R.A., Rees, J., Lacombe, D., Mason, W.P., Stupp, R., Baumert, B.G., Hegi, M.E., Bent, M.J. van den, Deimling, A. von, Gorlia, T., Hoang-Xuan, K., Brandes, A.A., Kantor, G., Taphoorn, M.J., Hassel, M.B., Hartmann, C., Ryan, G., Capper, D., Kros, J.M., Kurscheid, S., Wick, W., Enting, R., Reni, M., Thiessen, B., Dhermain, F., Bromberg, J.E., Feuvret, L., Reijneveld, J.C., Chinot, O., Gijtenbeek, J.M.M., Rossiter, J.P., Dif, N., Balana, C., Bravo-Marques, J., Clement, P.M., Marosi, C., Tzuk-Shina, T., Nordal, R.A., Rees, J., Lacombe, D., Mason, W.P., and Stupp, R.

Abstract

Item does not contain fulltext, BACKGROUND: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide chemotherapy in patients with low-grade glioma, and assessed progression-free survival outcomes and identified predictive molecular factors. METHODS: For this randomised, open-label, phase 3 intergroup study (EORTC 22033-26033), undertaken in 78 clinical centres in 19 countries, we included patients aged 18 years or older who had a low-grade (WHO grade II) glioma (astrocytoma, oligoastrocytoma, or oligodendroglioma) with at least one high-risk feature (aged >40 years, progressive disease, tumour size >5 cm, tumour crossing the midline, or neurological symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any condition that could interfere with oral drug administration. Eligible patients were randomly assigned (1:1) to receive either conformal radiotherapy (up to 50.4 Gy; 28 doses of 1.8 Gy once daily, 5 days per week for up to 6.5 weeks) or dose-dense oral temozolomide (75 mg/m2 once daily for 21 days, repeated every 28 days [one cycle], for a maximum of 12 cycles). Random treatment allocation was done online by a minimisation technique with prospective stratification by institution, 1p deletion (absent vs present vs undetermined), contrast enhancement (yes vs no), age (<40 vs >/=40 years), and WHO performance status (0 vs >/=1). Patients, treating physicians, and researchers were aware of the assigned intervention. A planned analysis was done after 216 progression events occurred. Our primary clinical endpoint was progression-free survival, analysed by intention-to-treat; secondary outcomes were overall survival, adverse events, neurocognitive function (will be reported separately), health-related quality of life and neurological function (reported separately), and correlative analyses of pro

Published
2016

45. A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548

Author

Weller, M., primary, Vlahovic, G., additional, Khasraw, M., additional, Brandes, A.A., additional, Zwirtes, R., additional, Tatsuoka, K., additional, Carpentier, A.F., additional, Reardon, D.A., additional, and Bent, Mvanden, additional

Published
2016
Full Text
View/download PDF

46. Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Author

Franceschi, E., primary, De Biase, D., additional, Paccapelo, A., additional, Reni, M., additional, Mura, A., additional, Tallini, G., additional, Bortolotti, C., additional, Volpin, L., additional, Marucci, G., additional, Cirillo, L., additional, Pession, A., additional, Ghimenton, C., additional, Poggi, R., additional, Bartolini, S., additional, Albini Riccioli, L., additional, Tosoni, A., additional, Degli Esposti, C., additional, Danieli, D., additional, Genestreti, G., additional, and Brandes, A.A., additional

Published
2016
Full Text
View/download PDF

47. The role of clinical risk in Low Grade Glioma patients in the era of genomic medicine: a GICNO study

Author

Franceschi, E., primary, De Biase, D., additional, Poggi, R., additional, Bartolini, S., additional, Fioravanti, A., additional, Bacci, A., additional, Zucchelli, M., additional, Zunarelli, E., additional, Depenni, R., additional, Di Battista, M., additional, Crisi, G., additional, Pizzolitto, S., additional, Pasini, G., additional, Dazzi, C., additional, Gamboni, A., additional, Mura, A., additional, and Brandes, A.A., additional

Published
2016
Full Text
View/download PDF

48. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer

Author

Di Bartolomeo, Maria, primary, Pietrantonio, Filippo, additional, Rulli, Eliana, additional, Poli, Davide, additional, Berenato, Rosa, additional, Caporale, Marta, additional, Bajetta, Emilio, additional, Floriani, Irene, additional, Bajetta, E., additional, Di Bartolomeo, M., additional, Catena, L., additional, Schiavo, M., additional, Pinotti, G., additional, Proserpio, I., additional, Rosati, G., additional, Bordonaro, R., additional, Cordio, S., additional, Burrafato, G., additional, Bochicchio, A.M., additional, Aieta, M., additional, Fazio, N., additional, Spada, F., additional, Amoroso, V., additional, Marini, G., additional, Soto Parra, H., additional, Novello, G., additional, Massidda, B., additional, Ionta, M.T., additional, Comandè, M., additional, Venezia, R., additional, Bertolini, A., additional, Menatti, E., additional, Zanlorenzi, L., additional, Colombo, A., additional, Iop, A., additional, Bonura, S., additional, Mazza, E., additional, Viganò, M., additional, Ardizzoia, A., additional, Dell'Oro, S., additional, Lo Re, G., additional, Santeufemia, D., additional, Buonadonna, A., additional, Luisi, D., additional, Ucci, G., additional, Di Lucca, G., additional, Bonetti, A., additional, Bergamo, F., additional, Alù, M., additional, Vastola, F., additional, Marchetti, P., additional, Corsi, D.C., additional, Massa, E., additional, Di Pinto, G., additional, Duro, M., additional, Oliani, C., additional, Franchini, M., additional, Inzoli, A., additional, Gebbia, N., additional, Repetto, L., additional, Rota, S., additional, Frontini, L., additional, Labianca, R., additional, Mosconi, S., additional, Quadri, A., additional, De Grossi, S., additional, Bidoli, P., additional, Cazzaniga, M.E., additional, Villa, F., additional, Foa, P., additional, Ferrari, D., additional, Aitini, E., additional, Rabbi, C., additional, Barni, S., additional, Petrelli, F., additional, Giordano, M., additional, Luchena, G., additional, Pirovano, M., additional, Nasisi, A., additional, Catalano, V., additional, Giordani, P., additional, Zaniboni, A., additional, Leone, F., additional, Ferrario, S., additional, Beretta, G.D., additional, Menichetti, E.T., additional, Conte, D., additional, Mari, D., additional, Giannicola, R., additional, Pierantoni, C., additional, Luporini, A.G., additional, Ragazzini, A., additional, Ravaioli, A., additional, Tassinari, D., additional, Nicolini, M., additional, Amadori, D., additional, Frassineti, G.L., additional, Turci, D., additional, Zumaglini, F., additional, Tamberi, S., additional, Piancastelli, A., additional, Cruciani, G., additional, Bejtja, E., additional, Falcone, A., additional, Landi, L., additional, Minuti, G., additional, Cantore, M., additional, Orlandi, M., additional, Mambrini, A., additional, Ciarlo, A., additional, Cavaciocchi, D., additional, Del Monte, F., additional, Ricci, S., additional, Brunetti, I.M., additional, Lencioni, M., additional, Sisani, M., additional, Sozzi, P., additional, Granetto, C., additional, Chiara, S., additional, Galetto, A.S., additional, Ribecco, A.S., additional, DeCensi, A., additional, Ciuffreda, L., additional, Baldini, E.E., additional, Camisa, R., additional, Todeschini, R., additional, Santoro, A., additional, Rimassa, L., additional, Carnaghi, C., additional, Pressiani, T., additional, Boni, C., additional, Rondini, E., additional, Gnoni, R., additional, Di Costanzo, F., additional, Gasperoni, S., additional, Cavanna, L., additional, Palladino, M.A., additional, Mattioli, R., additional, Laici, G., additional, Pucci, F., additional, Alessio, M.D., additional, Bernardini, I., additional, Tomasello, G., additional, Baldino, G., additional, Rossetti, R., additional, Giaquinta, S., additional, Pinto, C., additional, Di Fabio, F., additional, Rijas Llimpe, F.L., additional, Brandes, A.A., additional, Marzola, M., additional, Rummo Benevento, A.O.G., additional, Competiello, S., additional, Montesarchio, V., additional, Rea, A., additional, Daniele, B., additional, Genua, G., additional, Licenziato, M., additional, Casaretti, R., additional, Silvestro, L., additional, Montano, M., additional, Sarobba, M.G., additional, Sanna, G., additional, Filippelli, G., additional, Dima, G., additional, Greco, E., additional, Roselli, M., additional, Natale, D., additional, Condemi, G., additional, Fumi, G., additional, Tafuto, S., additional, Masullo, P., additional, Nitti, D., additional, Marchet, A., additional, Tiberio, G., additional, de Manzoni, G., additional, Nobili, S., additional, Fiorentini, G., additional, Mazzanti, R., additional, Perrotta, E., additional, Carlomagno, C., additional, De Stefano, A., additional, Cartenì, G., additional, and Otero, M., additional

Published
2016
Full Text
View/download PDF

49. 191PD_PR - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Author

Conte, P.F., Guarneri, V., Bisagni, G., Piacentini, F., Brandes, A.A., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Frassoldati, A., Musolino, A., Garrone, O., Taverniti, C., Rimanti, A., Sarti, S., Rubino, D., Bologna, A., Vicini, R., Balduzzi, S., and D'Amico, R.

Published
2018
Full Text
View/download PDF

50. 186O - Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Author

Dieci, M.V., Conte, P.F., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Omarini, C., Maiorana, A., Orvieto, E., Sanders, M., D'Amico, R., and Guarneri, V.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results